MedKoo product information:

 Leucovorin Calcium

leucovorin calcium is an active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs. Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

DRUG DESCRIPTION

Leucovorin Calcium Tablets contain either 5 mg or 25 mg leucovorin as the calcium salt of N-[4-[[(2-amino-5-formyl-1, 4, 5, 6, 7, 8-hexahydro-4-oxo-6-pteridinyl)-methyl]amino]benzoyl]-L-glutamic acid. This is equivalent to 5.40 mg or 27.01 mg of anhydrous leucovorin calcium. In addition each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The 25mg tablet also contains D&C yellow no. 10 and FD&C blue no. 1. Leucovorin is a water soluble form of reduced folate in the folate group; it is useful as an antidote to drugs which act as folic acid antagonists. These tablets are intended for oral administration only.

CLINICAL PHARMACOLOGY

Leucovorin is a racemic mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid. The biologically active compound of the mixture is the (-)-L-isomer, known as Citrovorum factor, or (-)-folinic acid. Leucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of "one-carbon" moieties. Following oral administration, leucovorin is rapidly absorbed and enters the general body pool of reduced folates. The increase in plasma and serum folate activity (determined microbiologically with Lactobacillus casei) seen after oral administration of leucovorin is predominantly due to 5-methyltetrahydrofolate.

Twenty normal men were given a single, oral 15 mg dose (7.5 mg/m2) of leucovorin calcium and serum folate concentrations were assayed with L. casei. Mean values observed (± one standard error) were:

1. Time to peak serum folate concentration: 1.72 ± 0.08 hours,
2. Peak serum folate concentration achieved: 268 ± 18 ng/mL,
3. Serum folate half-disappearance time: 3.5 hours.

Oral tablets yielded areas under serum folate concentration-time curves (AUCs) that were 12% greater than equal amoun

 1: Muro K. [Transition of chemotherapy for metastatic colorectal cancer and recent advances]. Nippon Rinsho. 2010 Jun;68(6):1143-9. Japanese. PubMed PMID: 20535969.

2: Paduch R, Kandefer-Szerszeń M, Piersiak T. The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs. Oncol Res. 2010;18(9):419-36. PubMed PMID: 20524400.

3: Hosoda K, Aoki M, Kido H, Natsu K, Tamura H, Kojima M, Amemiya T, Kamoshida T. [Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital]. Gan To Kagaku Ryoho. 2010 May;37(5):841-5. Japanese. PubMed PMID: 20495313.

4: Zhang H, Zhao C, Cao H, Wang G, Song L, Niu G, Yang H, Ma J, Zhu S. Hyperbranched poly(amine-ester) based hydrogels for controlled multi-drug release in combination chemotherapy. Biomaterials. 2010 Jul;31(20):5445-54. Epub 2010 Apr 10. PubMed PMID: 20382422.

5: Matsushita S, Ikeda R, Nishizawa Y, Che XF, Furukawa T, Miyadera K, Tabata S, Ushiyama M, Tajitsu Y, Yamamoto M, Takeda Y, Minami K, Mataki H, Kanzaki T, Yamada K, Kanekura T, Akiyama S. The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. Int J Oncol. 2010 May;36(5):1193-200. PubMed PMID: 20372793.

6: Sheen MC, Sheu HM, Jang MY, Chai CY, Wang YW, Wu CF. Advanced penile verrucous carcinoma treated with intra-aortic infusion chemotherapy. J Urol. 2010 May;183(5):1830-5. Epub 2010 Mar 29. PubMed PMID: 20303107.

7: Ishibashi K, Hokama N, Ishiguro T, Ohsawa T, Okada N, Miyazaki T, Yokoyama M, Inokuma S, Ishida H. [Treatment for intrapelvic recurrence of rectal cancer--resection versus chemotherapy]. Gan To Kagaku Ryoho. 2009 Nov;36(12):2226-8. Japanese. PubMed PMID: 20037378.

8: Surguladze D, Steiner P, Prewett M, Tonra JR. Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging. Methods Mol Biol. 2010;602:235-52. PubMed PMID: 20012402.

9: Kucherlapati MH, Lee K, Nguyen AA, Clark AB, Hou H Jr, Rosulek A, Li H, Yang K, Fan K, Lipkin M, Bronson RT, Jelicks L, Kunkel TA, Kucherlapati R, Edelmann W. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology. 2010 Mar;138(3):993-1002.e1. Epub 2009 Nov 18. PubMed PMID: 19931261; PubMed Central PMCID: PMC2862591.

10: Lladó V, Terés S, Higuera M, Alvarez R, Noguera-Salva MA, Halver JE, Escribá PV, Busquets X. Pivotal role of dihydrofolate reductase knockdown in the anticancer activity of 2-hydroxyoleic acid. Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13754-8. Epub 2009 Aug 3. PubMed PMID: 19666584; PubMed Central PMCID: PMC2720411.

11: Locke JM, Stutchbury TK, Vine KL, Gamble AB, Clingan PR, Bremner JB, Ranson M. Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate. Anticancer Drugs. 2009 Oct;20(9):822-31. PubMed PMID: 19606016.

12: Korbakis D, Scorilas A. Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12. Tumour Biol. 2009;30(2):100-7. Epub 2009 May 11. PubMed PMID: 19440006.

13: Takimoto N, Sugawara S, Iida A, Sakakibara T, Mori K, Sugiura M, Yamamura K, Adachi M. [Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer]. Gan To Kagaku Ryoho. 2009 Mar;36(3):431-5. Japanese. PubMed PMID: 19295267.

14: Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan PR, Avallone A, Budillon A. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther. 2009 May;8(9):782-91. Epub 2009 May 9. PubMed PMID: 19270508.

15: Yokoyama M, Ishibashi K, Hokama N, Ishiguro T, Miyazaki T, Matsuki M, Ishida H, Gika M, Yamahata T, Eguchi K, Nakayama M, Kikuchi K. [Problems involved in the resection of pulmonary metastasis from colorectal cancer in the era of new anticancer drugs]. Gan To Kagaku Ryoho. 2008 Nov;35(12):2198-200. Japanese. PubMed PMID: 19106569.

16: Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J. Lessons learned from independent central review. Eur J Cancer. 2009 Jan;45(2):268-74. PubMed PMID: 19101138.

17: Kurokawa Y, Sasako M. Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: adjuvant chemoradiotherapy for gastric cancer. Int J Clin Oncol. 2008 Dec;13(6):479-82. Epub 2008 Dec 18. Review. PubMed PMID: 19093173.

18: Yatsuda C, Niimi M, Ono Y, Uto N, Iwagami E, Tanaka E, Yamato M. [Epiphora in a patient receiving FOLFOX therapy]. Gan To Kagaku Ryoho. 2008 Nov;35(11):1989-91. Japanese. PubMed PMID: 19011359.

19: Priego S, Feddi F, Ferrer P, Mena S, Benlloch M, Ortega A, Carretero J, Obrador E, Asensi M, Estrela JM. Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. Mol Cancer Ther. 2008 Oct;7(10):3330-42. PubMed PMID: 18852136.

20: Dupuis C, Mercier C, Yang C, Monjanel-Mouterde S, Ciccolini J, Fanciullino R, Pourroy B, Deville JL, Duffaud F, Bagarry-Liegey D, Durand A, Iliadis A, Favre R. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs. 2008 Mar;19(3):267-73. PubMed PMID: 18510172.

21: Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother. 2008 Feb-Mar;31(2):132-47. PubMed PMID: 18481383.

22: Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen. J Chemother. 2008 Apr;20(2):278-81. PubMed PMID: 18467257.

23: Yoshimatsu K, Kuhara K, Itagaki H, Aizawa M, Yokomizo H, Fujimoto T, Otani T, Osawa G, Kobayashi R, Ogawa K. Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer. Anticancer Res. 2008 Jan-Feb;28(1B):373-8. PubMed PMID: 18383872.

24: Nduati E, Diriye A, Ommeh S, Mwai L, Kiara S, Masseno V, Kokwaro G, Nzila A. Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol Res. 2008 May;102(6):1227-34. Epub 2008 Feb 9. PubMed PMID: 18259776; PubMed Central PMCID: PMC2292483.

25: Di Lorenzo G, Rea A, Carlomagno C, Pepe S, Palmieri G, Labianca R, Chirianni A, De Stefano A, Esposito V, De Placido S, Montesarchio V. Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study. World J Gastroenterol. 2007 Dec 28;13(48):6553-7. PubMed PMID: 18161926.

26: Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007 Dec 10;25(35):5649-54. Review. PubMed PMID: 18065736.

27: Sakamoto E, Tsukioka S, Oie S, Kobunai T, Tsujimoto H, Sakamoto K, Okayama Y, Sugimoto Y, Oka T, Fukushima M, Oka T. Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun. 2008 Jan 25;365(4):801-7. Epub 2007 Nov 21. PubMed PMID: 18035049.

28: Ray-Coquard I, Bachelot T, Saba C, Confavreux C, Brantus JF, Rustam F, Ghesquière H, Sebban C, Biron P, Guastalla JP, Blay JY. [Are antiangiogenic antibodies universal for solid tumor?]. Bull Cancer. 2007 Jul;94 Spec No:S191-6. Review. French. PubMed PMID: 17846004.

29: Vormittag L, Kornek GV, Gruhsmann B, Lenauer A, Föger A, Depisch D, Lang F, Scheithauer W. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis. Anticancer Drugs. 2007 Jul;18(6):709-12. PubMed PMID: 17762401.

30: Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):1015-35. Epub 2007 Jul 4. Review. PubMed PMID: 17692427.

31: Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007 Jul 14;370(9582):143-52. Erratum in: Lancet. 2007 Aug 18;370(9587):566. PubMed PMID: 17630037.

32: Harned TM, Mascarenhas L. Severe methotrexate toxicity precipitated by intravenous radiographic contrast. J Pediatr Hematol Oncol. 2007 Jul;29(7):496-9. PubMed PMID: 17609630.

33: Yoshimatsu K, Yokomizo H, Fujimoto T, Umehara A, Otani T, Matsumoto A, Osawa G, Ogawa K. Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer. Anticancer Res. 2007 May-Jun;27(3B):1657-61. PubMed PMID: 17595792.

34: Al-Batran SE, Atmaca A, Schleyer E, Pauligk C, Hosius C, Ehninger G, Jäger E. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial. Cancer. 2007 May 1;109(9):1897-904. PubMed PMID: 17377918.

35: Neri B, Pantaleo P, Giommoni E, Grifoni R, Paoletti C, Rotella V, Pantalone D, Taddei A, Mercatelli A, Tonelli P. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer. 2007 Apr 10;96(7):1043-6. Epub 2007 Mar 13. PubMed PMID: 17353926; PubMed Central PMCID: PMC2360129.

36: Kobayashi R, Yoshimatsu K, Yokomizo H, Katsube T, Ogawa K. Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity. Anticancer Res. 2007 Jan-Feb;27(1B):675-9. PubMed PMID: 17348459.

37: Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):739-63. Epub 2007 Feb 16. Review. PubMed PMID: 17309673.

38: Nakahara O, Beppu T, Ishiko T, Mizumoto T, Masuda T, Hosaka S, Okabe H, Takamori H, Kanemitsu K, Hirota M, Baba H. [A long-term survival case of liver and mediastinal LN metastases from colon cancer treated with intensive multimodal therapy]. Gan To Kagaku Ryoho. 2006 Nov;33(12):1792-4. Japanese. PubMed PMID: 17212109.

39: Pasetto LM, Bortolami A, Falci C, Sinigaglia G, Monfardini S. Recent progress in target therapy in colorectal cancer. Anticancer Res. 2006 Sep-Oct;26(5B):3973-81. Review. PubMed PMID: 17094429.

40: Boku N, Okamoto R, Kandabashi K, Sasaki E, Omuro Y, Maeda Y, Sasaki T. [Clinicopathological characteristics of gastric cancer in elderly patients]. Gan To Kagaku Ryoho. 2006 Aug;33(8):1099-103. Japanese. PubMed PMID: 16912528.

41: Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F; European Organisation for Research and Treatment of Cancer Chronotherapy Group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006 Aug 1;24(22):3562-9. PubMed PMID: 16877722.

42: Arnold D, Peinert S, Voigt W, Schmoll HJ. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist. 2006 Jun;11(6):602-11. Review. PubMed PMID: 16794239.

43: Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. Cancer Res. 2006 Jun 1;66(11):5901-9. PubMed PMID: 16740730.

44: Shiah HS, Cheng AL, Hsu C, Hsu CH, Liu TW, Chang JY, Jan CM, Chao Y, Yu WL, Chuang TR, Whang-Peng J, Chen LT. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. J Gastroenterol Hepatol. 2006 Mar;21(3):531-6. PubMed PMID: 16638094.

45: Ardavanis AS, Ioannidis GN, Orphanos GS, Rigatos GA. Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer. Anticancer Res. 2006 Mar-Apr;26(2B):1669-72. PubMed PMID: 16619589.

46: Lévi F. Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control. 2006 May;17(4):611-21. Review. PubMed PMID: 16596317.

47: Poujol S, Bressolle F, Duffour J, Abderrahim AG, Astre C, Ychou M, Pinguet F. Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. Cancer Chemother Pharmacol. 2006 Sep;58(3):292-305. Epub 2005 Dec 21. PubMed PMID: 16369821.

48: Yamashita K, Urakami A, Kubozoe T, Ikeda M, Hirabayashi Y, Yamamura M, Iki K, Akiyama T, Matsumoto H, Hirai T, Sadahira Y, Tsunoda T. In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer. Int J Clin Oncol. 2005 Oct;10(5):328-32. PubMed PMID: 16247659.

49: Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 2005 Dec 10;23(35):8950-8. Epub 2005 Aug 1. PubMed PMID: 16061910.

50: Pestalozzi BC, Jäger D, Knuth A. [Systemic therapy for colorectal cancer]. Chirurg. 2005 Jun;76(6):570-2, 574. German. PubMed PMID: 15905968.

51: Peters GJ, Smorenburg CH, Van Groeningen CJ. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. J Chemother. 2004 Nov;16 Suppl 4:25-30. Review. PubMed PMID: 15688605.

52: Gupta S, Mauer AM, Ryan CW, Taber DA, Samuels BL, Fleming GF; University of Chicago Phase II Network. A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. Am J Clin Oncol. 2005 Feb;28(1):65-9. PubMed PMID: 15685037.

53: Gmeiner WH. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem. 2005;12(2):191-202. Review. PubMed PMID: 15638735.

54: Medinger M, Steinbild S, Mross K. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004]. Praxis (Bern 1994). 2004 Sep 29;93(40):1633-44. Review. German. PubMed PMID: 15495753.

55: Olivieri AC, Arancibia JA, Muñoz de la Peña A, Durán-Merás I, Espinosa Mansilla A. Second-order advantage achieved with four-way fluorescence excitation-emission-kinetic data processed by parallel factor analysis and trilinear least-squares. Determination of methotrexate and leucovorin in human urine. Anal Chem. 2004 Oct 1;76(19):5657-66. PubMed PMID: 15456283.

56: Rustum YM. Thymidylate synthase: a critical target in cancer therapy? Front Biosci. 2004 Sep 1;9:2467-73. Review. PubMed PMID: 15353299.

57: Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, Gamelin E. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61. PubMed PMID: 15217938.

58: Casale F, Canaparo R, Serpe L, Muntoni E, Pepa CD, Costa M, Mairone L, Zara GP, Fornari G, Eandi M. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res. 2004 Aug;50(2):173-9. PubMed PMID: 15177306.

59: Yagyu T, Aihara T, Murayama M, Nakamura E, Nozaki H, Niida M, Yasuoka H, Nishimoto Y, Watanabe Y, Syouda S, Kouno T, Fukuhara A, Nakagawa K. [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11]. Gan To Kagaku Ryoho. 2004 Mar;31(3):431-3. Japanese. PubMed PMID: 15045956.

60: Morishita Y, Kasakura Y, Fujii M, Kochi M, Sato K, Kobayashi M, Takayama T. [A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11]. Gan To Kagaku Ryoho. 2004 Mar;31(3):427-30. Japanese. PubMed PMID: 15045955.

61: Cats A. New developments in systemic chemotherapy in advanced colorectal cancer. Scand J Gastroenterol Suppl. 2003;(239):78-86. Review. PubMed PMID: 14743888.

62: Okabe S, Arai T, Yamashita H, Sugihara K, Sasaki T. Randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP, 5-FU and dl-leucovorin for advanced colorectal cancer. J Gastroenterol Hepatol. 2004 Jan;19(1):56-62. PubMed PMID: 14675243.

63: Matsui A, Okuda M, Tsujitsuka K, Enomoto K, Maruyama K. Pharmacology of intraperitoneal CPT-11. Surg Oncol Clin N Am. 2003 Jul;12(3):795-811, xv. Review. PubMed PMID: 14567032.

64: Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, Giannarelli D, Cognetti F. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol. 2003 Sep;14(9):1378-82. PubMed PMID: 12954576.

65: Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54. PubMed PMID: 12874005.

66: Focan C, Focan-Henrard D, Kreutz F, Moeneclaey N. [Chronobiological considerations for the management of human head and neck cancer]. Pathol Biol (Paris). 2003 Jun;51(4):201-3. French. PubMed PMID: 12852988.

67: Urien S, Fumoleau P, Campone M, Kerbrat P, Bonneterre J, Fargeot P, Deporte-Fety R. Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Cancer Chemother Pharmacol. 2003 Aug;52(2):99-107. Epub 2003 May 27. PubMed PMID: 12768319.

68: Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5. Review. PubMed PMID: 12577232.

69: Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. Anticancer Res. 2002 Nov-Dec;22(6B):3621-7. PubMed PMID: 12552966.

70: Mormont MC, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer. 2003 Jan 1;97(1):155-69. Review. PubMed PMID: 12491517.

71: Lehman NL. Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs. 2002 Dec;11(12):1775-87. Review. PubMed PMID: 12457437.

72: Berlin JD. Targeting vascular endothelial growth factor in colorectal cancer. Oncology (Williston Park). 2002 Aug;16(8 Suppl 7):13-5. Review. PubMed PMID: 12199627.

73: Furue H. [Prevention of side reactions--present status and problems--special references]. Gan To Kagaku Ryoho. 2002 Jul;29(7):1325-30. Review. Japanese. PubMed PMID: 12146019.

74: Hasegawa Y. [Chemo-radiotherapy for head and neck cancer]. Gan To Kagaku Ryoho. 2002 May;29(5):677-83. Review. Japanese. PubMed PMID: 12040670.

75: Gusella M, Ferrazzi E, Ferrari M, Padrini R. New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus. Ther Drug Monit. 2002 Jun;24(3):425-31. PubMed PMID: 12021636.

76: Giacchetti S. Chronotherapy of colorectal cancer. Chronobiol Int. 2002 Jan;19(1):207-19. PubMed PMID: 11962676.

77: McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs. 2001;61(15):2309-26. Review. PubMed PMID: 11772141.

78: Nehls O, Porschen R, Gregor M, Klump B. [The role of oxaliplatin in the therapy for advanced colorectal carcinoma]. Z Gastroenterol. 2001 Dec;39(12):1033-47. Review. German. PubMed PMID: 11753789.

79: Baba H, Maruyama M, Toukairin Y, Kure N, Nagahama T, Ebuchi M. [A case of advanced gastric cancer with multiple liver metastases partially responding to combination intra-arterial chemotherapy via the hepatic artery and abdominal aorta]. Gan To Kagaku Ryoho. 2001 Oct;28(11):1732-5. Japanese. PubMed PMID: 11708020.

80: Grivicich I, Mans DR, Peters GJ, Schwartsmann G. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. Braz J Med Biol Res. 2001 Sep;34(9):1087-103. Review. PubMed PMID: 11514832.

81: Caponigro F, Avallone A, Budillon A, Comella P, Comella G. Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy. Anticancer Drugs. 2001 Jul;12(6):489-97. Review. PubMed PMID: 11459994.

82: Ohta K, Sawamura A, Miyahara E, Kim R, Toge T. [A case of inoperable advanced gall bladder cancer responding to intra-arterial infusion of 5-fluorouracil (5-FU) and leucovorin (LV)]. Gan To Kagaku Ryoho. 2001 Apr;28(4):516-9. Japanese. PubMed PMID: 11329787.

83: Cowan DS, Tannock IF. Factors that influence the penetration of methotrexate through solid tissue. Int J Cancer. 2001 Jan 1;91(1):120-5. PubMed PMID: 11149410.

84: Ogawa M. Current Status and Perspectives in Cancer Chemotherapy. Breast Cancer. 1999 Oct 25;6(4):270-274. PubMed PMID: 11091728.

85: Wilke H, Stahl M, Köster W, Vanhöfer U. [Infusiontherapy with 5-fluorouracil ("infusional" 5-FU) in solid tumors]. Med Klin (Munich). 2000 Jun;95 Suppl 1:3-8. Review. German. PubMed PMID: 10941246.

86: Hoff PM, Lassere Y, Pazdur R. Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. Drugs. 1999;58 Suppl 3:77-83. Review. PubMed PMID: 10711845.

87: Sharma S, Jagdev S, Coleman RE, Hancock BW, Lorigan PC. Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. Br J Cancer. 1999 Nov;81(6):1037-41. PubMed PMID: 10576662; PubMed Central PMCID: PMC2362938.

88: Lévi F. Cancer chronotherapy. J Pharm Pharmacol. 1999 Aug;51(8):891-8. Review. PubMed PMID: 10504026.

89: Tan Y, Sun X, Xu M, Tan X, Sasson A, Rashidi B, Han Q, Tan X, Wang X, An Z, Sun FX, Hoffman RM. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res. 1999 Aug;5(8):2157-63. PubMed PMID: 10473100.

90: Skelton LA, Ormerod MG, Titley J, Kimbell R, Brunton LA, Jackman AL. A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus. Br J Cancer. 1999 Apr;79(11-12):1692-701. PubMed PMID: 10206279; PubMed Central PMCID: PMC2362793.

91: Falcone A, Pfanner E, Brunetti I, Allegrini G, Lencioni M, Galli C, Masi G, Danesi R, Antonuzzo A, Del Tacca M, Conte PF. Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy. Tumori. 1998 Nov-Dec;84(6):666-8. PubMed PMID: 10080673.

92: McLeod HL, Sludden J, Hardy SC, Lock RE, Hawksworth GM, Cassidy J. Autoregulation of 5-fluorouracil metabolism. Eur J Cancer. 1998 Sep;34(10):1623-7. PubMed PMID: 9893640.

93: Miya K, Adachi T, Nagao N, Takagi Y, Kawaguchi Y, Kato M, Takao H, Sugiyama Y, Kunieda K, Umemoto T, Fukada D, Saji S. [Clinical evaluation of intermittent hepatic arterial infusion therapy for metastatic liver tumor of gastric and colorectal cancer]. Gan To Kagaku Ryoho. 1998 Jul;25(9):1397-401. Japanese. PubMed PMID: 9703838.

94: Gamelin E, Boisdron-Celle M, Lebouil A, Turcant A, Cailleux A, Krikorian A, Brienza S, Cvitkovic E, Larra F, Robert J, Allain P. Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters. Anticancer Drugs. 1998 Mar;9(3):223-8. PubMed PMID: 9625432.

95: Ducreux M, Louvet C, Bekradda M, Cvitkovic E. Oxaliplatin for the treatment of advanced colorectal cancer: future directions. Semin Oncol. 1998 Apr;25(2 Suppl 5):47-53. Review. PubMed PMID: 9609108.

96: Keshava C, Keshava N, Whong WZ, Nath J, Ong TM. Inhibition of methotrexate-induced chromosomal damage by folinic acid in V79 cells. Mutat Res. 1998 Feb 2;397(2):221-8. PubMed PMID: 9541646.

97: Danesi R, Falcone A, Conte PF, Del Tacca M. Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine. Clin Pharmacokinet. 1998 Feb;34(2):173-80. Review. PubMed PMID: 9515187.

98: Clark JW. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-19-S18-24. Review. PubMed PMID: 9420017.

99: Kawabe S, Takiuchi H, Hirata I, Takao Y, Nakagawa K, Egashira Y, Nakagawa Y, Katsu K. [A case of recurrent advanced colon cancer treated with CPT-11 for second-line chemotherapy]. Gan To Kagaku Ryoho. 1997 Aug;24(10):1315-9. Japanese. PubMed PMID: 9279352.

100: Baxevanis CN, Tsavaris NB, Papadhimitriou SI, Zarkadis IK, Papadopoulos NG, Bastounis EA, Papamichail M. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses. Eur J Cancer. 1997 Jul;33(8):1202-8. PubMed PMID: 9301443.

101: Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM, Boyle FT. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res. 1997 Jun;3(6):911-21. PubMed PMID: 9815766.

102: Meurman JH, Laine P, Keinànen S, Pyrhönen S, Teerenhovi L, Lindqvist C. Five-year follow-up of saliva in patients treated for lymphomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Apr;83(4):447-52. PubMed PMID: 9127375.

103: Okabe H, Toko T, Saito H, Nakano K, Fujioka A, Yuasa C, Takeda S, Unemi N. Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5-fluorouracil] with uracil, by oral l-leucovorin. Anticancer Res. 1997 Jan-Feb;17(1A):157-64. PubMed PMID: 9066646.

104: Seelig MH, Berger MR. Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. Eur J Cancer. 1996 Oct;32A(11):1968-76. PubMed PMID: 8943683.

105: Sugiyama Y, Saji S, Miya K, Fukada D, Umemoto T, Kunieda K, Takao H, Kato M, Kawai M. [Locoregional therapy for liver metastases of colorectal cancer]. Gan To Kagaku Ryoho. 1996 Sep;23(11):1433-6. Japanese. PubMed PMID: 8854772.

106: Kemeny N. Colorectal cancer--an undertreated disease. Anticancer Drugs. 1996 Aug;7(6):623-9. Review. PubMed PMID: 8913429.

107: Lévi F. Chronotherapy for gastrointestinal cancers. Curr Opin Oncol. 1996 Jul;8(4):334-41. Review. PubMed PMID: 8869810.

108: Ishikawa T, Ishikawa N, Oota H, Yoshida T, Honma A, Kamimura T, Takeda K, Ishikawa N, Ozaki T. [A case of common bile duct cancer responding to MMC leucovorin, 5-FU, and UFT combination chemotherapy and radiation]. Gan To Kagaku Ryoho. 1996 May;23(6):773-7. Japanese. PubMed PMID: 8645028.

109: Chi KH, Chan WK, Shu CH, Law CK, Chen SY, Yen SH, Chen KY. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer. 1995 Dec 1;76(11):2186-92. PubMed PMID: 8635020.

110: Yuasa C, Okabe H, Toko T, Takeda S, Unemi N. [Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil]. Gan To Kagaku Ryoho. 1995 Nov;22(13):1927-32. Japanese. PubMed PMID: 7487122.

111: Saito H, Okabe H, Nakano K, Fujioka A, Toko T, Takeda S, Unemi N. [Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--growth-inhibitory activity of combination against human tumor xenograft]. Gan To Kagaku Ryoho. 1995 Nov;22(13):1919-25. Japanese. PubMed PMID: 7487121.

112: Sugiyama Y, Saji S, Miya K, Fukada D, Umemoto T, Kunieda K, Takao H, Kato M, Tsuji K. [A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer]. Gan To Kagaku Ryoho. 1995 Sep;22(11):1460-3. Japanese. PubMed PMID: 7574732.

113: Strømhaug A, Warren DJ, Slørdal L. Effect of methotrexate on murine bone marrow cells in vitro: evidence of a reversible antiproliferative action. Exp Hematol. 1995 May;23(5):439-43. PubMed PMID: 7720815.

114: Lygidakis NJ, Pothoulakis J, Konstantinidou AE, Spanos H. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res. 1995 Mar-Apr;15(2):543-50. PubMed PMID: 7539237.

115: Milano G. [Increase of dose intensity by pharmacomodulation. General concepts and therapeutic applications]. Bull Cancer. 1995;82 Suppl 1:37s-41s. French. PubMed PMID: 7626853.

116: Lévi F. [Chrono-chemotherapy and dose intensity]. Bull Cancer. 1995;82 Suppl 1:29s-36s. French. PubMed PMID: 7626851.

117: Cerruti A, Castello G, Balleari E, Bogliolo G, Lerza R, Pannacciulli I. Serum erythropoietin increase in patients receiving adjuvant therapy with 5-fluorouracil and leucovorin. Exp Hematol. 1994 Dec;22(13):1261-3. PubMed PMID: 7957712.

118: Uchida K, Hayashi T, Shiga T, Hattori K, Nishijima Y, Kasaya S, Shimazui T, Akaza H, Koiso K, Nemoto R, et al. [Treatment of prostatic carcinoma with UFT and leucovorin--basic study using SRCA]. Gan To Kagaku Ryoho. 1994 Nov;21(15):2633-7. Japanese. PubMed PMID: 7979424.

119: van der Wilt CL, Peters GJ. New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase. Pharm World Sci. 1994 Apr 15;16(2):84-103. Review. Erratum in: Pharm World Sci 1994 Jun 10;16(3):167. PubMed PMID: 7518280.

120: Keizer HJ, De Bruijn EA, Tjaden UR, De Clercq E. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. J Cancer Res Clin Oncol. 1994;120(9):545-9. PubMed PMID: 8045919.

121: Wainer IW, Granvil CP. Stereoselective separations of chiral anticancer drugs and their application to pharmacodynamic and pharmacokinetic studies. Ther Drug Monit. 1993 Dec;15(6):570-5. Review. PubMed PMID: 8122296.

122: Pologeorgis G, Agnantis N, Kottaridis S. Regional intraarterial infusion of methotrexate with leucovorin rescue in a rat tumor model. Anticancer Res. 1993 Nov-Dec;13(6A):2193-9. PubMed PMID: 8297133.

123: Hojyo M, Maruo H, Kosaka A. [Reservoir system implantation technique via the inferior epigastric artery for local recurrence of rectal cancer]. Gan To Kagaku Ryoho. 1993 Oct;20(13):1977-81. Japanese. PubMed PMID: 8215471.

124: Wainer IW. Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing. Ann Oncol. 1993;4 Suppl 2:7-13. Review. PubMed PMID: 8353104.

125: Laine P, Meurman JH, Tenovuo J, Murtomaa H, Lindqvist C, Pyrhönen S, Teerenhovi L. Salivary flow and composition in lymphoma patients before, during and after treatment with cytostatic drugs. Eur J Cancer B Oral Oncol. 1992 Oct;28B(2):125-8. PubMed PMID: 1284874.

126: Frykholm G, Hemmingsson A, Nyman R, Påhlman L, Glimelius B. Nonresectable adenocarcinoma of the rectum assessed by MR imaging before and after chemotherapy and irradiation. Acta Radiol. 1992 Sep;33(5):447-52. PubMed PMID: 1389653.

127: Tsukagoshi S. [Biochemical modulation--the historical background]. Gan To Kagaku Ryoho. 1992 Jul;19(7):941-5. Review. Japanese. PubMed PMID: 1626949.

128: Nakamura T, Ueda T, Uchida M. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)]. Gan To Kagaku Ryoho. 1992 Mar;19(3):409-20. Review. Japanese. PubMed PMID: 1543370.

129: Nakamura T, Uchida M, Ueda T. [Clinical pharmacology of anticancer agents (Part 4). Antimetabolites (1)]. Gan To Kagaku Ryoho. 1992 Feb;19(2):265-76. Japanese. PubMed PMID: 1736842.

130: Okamoto H, Saijo N. [Preclinical trials from the standpoint of clinical trials]. Gan To Kagaku Ryoho. 1991 Jul;18(9):1467-75. Japanese. PubMed PMID: 1854217.

131: Dorr RT. Chemoprotectants for cancer chemotherapy. Semin Oncol. 1991 Feb;18(1 Suppl 2):48-58. Review. PubMed PMID: 1899489.

132: Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990 Oct;8(10):1739-53. Review. PubMed PMID: 2213109.

133: Arbuck SG. Overview of chemotherapy for pancreatic cancer. Int J Pancreatol. 1990 Aug-Nov;7(1-3):209-22. Review. PubMed PMID: 2081925.

134: Bruckner HW, Spigelman M. Leucovorin as a clinical potentiator of 5-fluorouracil toxicity and anticancer efficacy. Mt Sinai J Med. 1988 Oct;55(5):390-4. PubMed PMID: 3265179.

135: DeLap RJ. The effect of leucovorin on the therapeutic index of fluorouracil in cancer patients. Yale J Biol Med. 1988 Jan-Feb;61(1):23-34. Review. PubMed PMID: 3284210; PubMed Central PMCID: PMC2590394.

136: Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest. 1987 Feb;79(2):478-82. PubMed PMID: 2948969; PubMed Central PMCID: PMC424107.

137: Rustum YM, Radel S, Campbell J, Mayhew E. Approaches to overcome in vivo anti-cancer drug resistance. Prog Clin Biol Res. 1986;223:187-202. PubMed PMID: 3492716.

138: Takaku F. [High-dose treatment]. Gan To Kagaku Ryoho. 1985 Apr;12(4):830-8. Japanese. PubMed PMID: 3872631.

139: Przybylski M, Preiss J, Dennebaum R, Fischer J. Identification and quantitation of methotrexate and methotrexate metabolites in clinical high-dose therapy by high pressure liquid chromatography and field desorption mass spectrometry. Biomed Mass Spectrom. 1982 Jan;9(1):22-32. PubMed PMID: 7037062.

140: Armand JP. [New anticancer chemotherapy]. Rev Infirm. 1981 Nov;31(17):35-9. French. PubMed PMID: 6977176.

141: Lankelma J, van der Kleijn E, Jansen MJ. Determination of 5-methyltetrahydrofolic acid in plasma and spinal fluid by high-performance liquid chromatography, using on-column concentration and electrochemical detection. J Chromatogr. 1980 Apr 11;182(1):35-45. PubMed PMID: 6966631.

142: Chabner BA, Myers CE, Oliverio VT. Clinical pharmacology of anticancer drugs. Semin Oncol. 1977 Jun;4(2):165-91. PubMed PMID: 69319.

143: Orbach-Arbouys S. [Rupture immune tolerance by some cytostatic agents used in anticancer chemotherapy]. Rev Fr Etud Clin Biol. 1968 Dec;13(10):1014-6. French. PubMed PMID: 5306737.

144: FUJII M. STUDIES ON THE HEME SYNTHESIS BY BONE MARROW CELLS IN VITRO AND IN VIVO WITH 2-14C-GLYCINE. III. EFFECTS OF VITAMINS AND ANTICANCER AGENTS ON HEME SYNTHESIS BY RABBIT BONE MARROW CELLS IN VITRO. Naika Hokan. 1964 Mar;11:111-5. PubMed PMID: 14163641.